Serum β-Klotho concentrations are increased in women with polycystic ovary syndrome

• Published in: Cytokine (Philadelphia, Pa.) Pa.), 2020-10, Vol.134, p.155188-155188, Article 155188
• Main Authors: Bednarska, Sylwia, Fryczak, Jolanta, Siejka, Agnieszka
• Format: Article
• Language: English
• Subjects: FGF19; FGF21; Klotho; PCOS
• ISSN: 1043-4666; 1096-0023
• DOI: 10.1016/j.cyto.2020.155188

•The concentrations of β-Klotho, FGF19 and FGF21 are significantly increased in the sera of patients with PCOS.•Elevated β-Klotho concentration may become an useful diagnostic test for PCOS.•FGF19, FGF21 and β-Klotho may be involved in the pathogenesis of this disease. Polycystic ovary syndrome (PCOS) is a significant cause of menstrual disorders and infertility in women. The aim of this study was to evaluate the levels of Klotho expression in women with polycystic ovary syndrome. The study involved 67 patients with PCOS, as well as 18 controls. Serum levels of FGF19, FGF21 and β-Klotho were measured by ELISA technique. The blood samples were obtained between days 2 and 7 of menstrual cycle. The concentrations of β-Klotho, FGF19 and FGF21 were significantly increased in patients with PCOS; and appear to be statistically significant predictors of PCOS incidence. FGF19 (p = 0.031, OR = 1.01), exact β-Klotho levels (p = 0.022, OR = 1.01) and β-Klotho beyond the reference range (p = 0.008, OR = 4.66) were the most strongly correlated with the diagnosis of PCOS. In conclusion, FGF19, FGF21 and β-Klotho are increased in PCOS, and elevated β-Klotho concentration may become an useful diagnostic test for this disease. However, additional studies are required to further substantiate this observation.